Немуковисцидозные бронхоэктазы: современный взгляд на проблему, перспективы лечения

Автор: Синицын Евгений Александрович, Зыков Кирилл Алексеевич

Журнал: Клиническая практика @clinpractice

Статья в выпуске: 4 т.9, 2018 года.

Бесплатный доступ

В обзоре представлены современные данные по этиологии, эпидемиологии, патогенезу немуковисцидозных бронхоэктазов, а также тенденции в развитии современных методов лечения.

Немуковисцидозные бронхоэктазы, эпидемиология, патогенез, лечение, рекомендации

Короткий адрес: https://sciup.org/143166569

IDR: 143166569 | DOI: 10.17816/clinpract9455-64

Список литературы Немуковисцидозные бронхоэктазы: современный взгляд на проблему, перспективы лечения

Laënnec RTH. On mediate auscultation, or a treatise on the diagnosis of diseases of the lungs and heart. In: De l’auscultation médiate ou trait du diagnostic des maladies des poumon et du coeur. 1st ed. Paris: Brosson & Chaudé; 1819.
Polverino E., Goeminne PC, McDonnell MJ, et al. European Respiratory Society guidelines for the management of adult bronchiectasis. Eur Respir J. 2017; 50(3): 1700629 DOI: 10.1183/13993003.006292017
Национальные клинические рекомендации «Наг-ноительные заболевания легких» ./Под ред. ЕА Корымасова. -М.; 2015. Доступно по: http://zodorov.ru/nacionalenie-klinicheskie-rekomendacii-nagnoitelenie-zabolevan.html. Ссылка активна на 12.08.2018.
McGuinness G., Naidich DP CT of airways disease and bronchiectasis. Radiol Clin North Am. 2002; 40(1): 1-19 DOI: 10.1016/s0033-8389(03)00105-2
ten Hacken NH, van der Molen T. Bronchiectasis BMJ. 2010; 341: c2766 DOI: 10.1136/bmj.c2766
Seitz AE, Olivier KN, Adjemian J., et al. Trends in bronchiectasis among Medicare beneficiaries in the United States, 2000 to 2007. Chest. 2012; 142(2): 432-439 DOI: 10.1378/chest.11-2209
Martinez-Garcia MÂ, Mâiz L., Olveira C., et al. Spanish guidelines on the evaluation and diagnosis of bronchiectasis in adults Arch Bronconeumol. 2018; 54(2): 79-87 DOI: 10.1016/j.arbres.2017.07.015
McShane PJ, Naureckas ET, Tino G., Strek ME. Non-cystic fibrosis bronchiectasis. Am J. Respir Crit Care Med. 2013; 188(6): 647-656 DOI: 10.1164/rccm.201303-0411CI
Goeminne PC, Scheers H., Decraene A., et al. Risk factors for morbidity and death in non-cystic fibrosis bronchiectasis: a retrospective cross-sectional analysis of CT diagnosed bronchiectatic patients. Respir Res. 2012; 13: 21 DOI: 10.1186/1465-9921-13-21
Loebinger MR,Wells AU,Hansell DM, et al. Mortalityin bronchiectasis: a long-term study assessing the factors influencing survival. Eur Respir J. 2009; 34(4): 843-849 DOI: 10.1183/09031936.00003709
Onen ZP, Gulbay BE, Sen E., et al. Analysis of the factors related to mortality in patients with bronchiectasis. Respir Med. 2007; 101(7): 1390-1397 DOI: 10.1016/j.rmed.2007.02.002
Weycker D., Edelsberg J., Oster G., Tino G. Prevalence and economic burden of bronchiectasis. Clin Pulm Med. 2005; 12(4): 205-209 DOI: 10.1097/01.cpm.0000171422.98696.ed
Olveira C., Padilla A., Martinez-Garcia MÂ, et al. Etiology of bronchiectasis in a cohort of 2047 patients. An analysis of the Spanish Historical Bronchiectasis Registry. Arch Bronconeumol. 2017; 53(7): 366-374 DOI: 10.1016/j.arbres.2016.12.003
Pasteur MC, Helliwell SM, Houghton SJ, et al. An investigation into causative factors in patients with bronchiectasis. Am J. Respir Crit Care Med. 2000; 162(4 Pt 1): 1277-1284 DOI: 10.1164/ajrccm.162.4.9906120
Shoemark A, Ozerovitch L, Wilson R. Aetiology in adult patients with bronchiectasis. Respir Med. 2007; 101(6): 1163-1170 DOI: 10.1016/j.rmed.2006.11.008
King PT, Holdsworth SR, Freezer NJ, et al. Microbiologic follow-up study in adult bronchiectasis. Respir Med. 2007; 101(8): 1633-1638. doi: 10.1016/j. rmed.2007.03.009.
Davies G, Wells AU, Doffman S, et al. The effect of Pseudomonas aeruginosa on pulmonary function in patients withbronchiectasis. Eur Respir J. 2006; 28(5): 974-979 DOI: 10.1183/09031936.06.00074605
McShane PJ, Naureckas ET, Strek ME. Bronchiectasis in a diverse US population: effects of ethnicity on etiology and sputum culture. Chest. 2012; 142(1): 159-167 DOI: 10.1378/chest.11-1024
Wilson CB, Jones PW, O’Leary CJ, et al. Effect of sputum bacteriology on the quality of life of patients with bronchiectasis. Eur Respir J. 1997; 10(8): 1754-1760 DOI: 10.1183/09031936.97.10081754
Evans SA,Turner SM, Bosch BJ, et al. Lung function in bronchiectasis: the influence of Pseudomonas aeruginosa. Eur Respir J. 1996; 9(8): 1601-1604 DOI: 10.1183/09031936.96.09081601
Wang H, Ji XB, Mao B, et al. Pseudomonas aeruginosa isolation in patients with non-cystic fibrosis bronchiectasis: a retrospective study. BMJ Open. 2018; 8(3): e014613 DOI: 10.1136/bmjopen-2016-014613
Falkinham JO. Impact of human activities on the ecology of nontuberculous mycobacteria. Future Microbiol. 2010; 5(6): 951-960 DOI: 10.2217/fmb.10.53
De Vries SP, Bootsma HJ, Hays JP, Hermans PW. Molecular aspects of Moraxella catarrhalispathogenesis. Microbiol Mol Biol Rev. 2009; 73(3): 389-406 DOI: 10.1128/MMBR.00007-09
Donlan RM, Costerton JW. Biofilms: survival mechanisms of clinically relevant microorganisms. Clin Microbiol Rev. 2002; 15(2): 167-193 DOI: 10.1128/cmr.15.2.167-193.2002
Hall-Stoodley L, Keevil CW, Lappin-Scott HM. Mycobacterium fortuitum and Mycobacterium chelonae biofilm formation under high and low nutrient conditions. J Appl Microbiol. 1998; 85 Suppl 1: 60S-69S DOI: 10.1111/j.1365-2672.1998.tb05284.x
Otto M. Staphylococcal biofilms. Curr Top Microbiol Immunol. 2008; 322: 207-228 DOI: 10.1007/978-3-540-75418-3_10
Респираторная медицина: руководство: в 3 т./Под ред. АП Чучалина. 2-е изд., перераб. и доп. -М.: Литтерра; 2017. -Т1. -640 с.
Cotran RS, Kumar V, Collins T. Robins pathologic basis of diseases. Philadilphia: J.B. Saunders Company. 6th edition; 2008.
Chalmers JD, Chotirmall SH. Bronchiectasis: new therapies and new perspectives. Lancet Respir Med. 2018; 6(9): 715-726 DOI: 10.1016/S2213-2600(18)30053-5
Murray MP, Govan JR, Doherty CJ, et al. A randomized controlled trial of nebulized gentamicin in non-cystic fibrosis bronchiectasis. Am J Respir Crit Care Med. 2011; 183(4): 491-499 DOI: 10.1164/rccm.201005-0756OC
Barker AF, Couch L, Fiel SB, et al. Tobramycin solution for inhalation reduces sputum Pseudomonas aeruginosa density in bronchiectasis. Am J Respir Crit Care Med. 2000; 162(2 Pt 1): 481-485 DOI: 10.1164/ajrccm.162.2.9910086
Haworth CS, Foweraker JE, Wilkinson P, et al. Inhaled colistin in patients with bronchiectasis and chronic pseudomonas aeruginosa infection. Am J Respir Crit Care Med. 2014; 189(8): 975-982 DOI: 10.1164/rccm.201312-2208OC
Barker AF O’Donnell AE, Flume P, et al. Aztreonam for inhalation solution in patients with non-cystic fibrosis bronchiectasis (AIR-BX1 and AIR-BX2): two randomized double-blind, placebo-controlled phase 3 trials. Lancet Respir Med. 2014; 2(9): 738-749 DOI: 10.1016/S2213-2600(14)70165-1
Haworth C, Wanner A, Froehlich J, et al. Inhaled liposomal ciprofloxacin in patients with bronchiectasis and chronic Pseudomonas aeruginosa infection: results from two parallel phase III trials (ORBIT 3 and 4). Am J Respir Crit Care Med. 2017; 195: A7604.
De Soyza A, Aksamit T, Bandel TJ, et al. RESPIRE 1: a phase III placebo-controlled randomised trial of ciprofloxacin dry powder for inhalation in non-cystic fibrosis bronchiectasis. Eur Respir J. 2018; 51(1): 1702052 DOI: 10.1183/13993003.020522017
Aksamit T, De Soyza A, Bandel TJ, et al. RESPIRE 2: a phase III placebo-controlled randomised trial of ciprofloxacin dry powder for inhalation in non-cystic fibrosis bronchiectasis. Eur Respir J. 2018; 51(1): 1702053 DOI: 10.1183/13993003.020532017
Serisier DJ, Martin ML, McGuckin MA, et al. Effect of long-term, low-dose erythromycin on pulmonary exacerbations among patients with non-cystic fibrosis bronchiectasis: the BLESS randomized controlled trial. JAMA. 2013; 309(12): 1260-1267 DOI: 10.1001/jama.2013.2290
Altenburg J, de Graaff CS, Stienstra Y et al. Effect of azithromycin maintenance treatment on infectious exacerbations among patients with non-cystic fibrosis bronchiectasis: the BAT randomized controlled trial. JAMA. 2013; 309(12): 1251-1259 DOI: 10.1001/jama.2013.1937
Wong C, Jayaram L, Karalus N, et al. Azithromycin for prevention of exacerbations in non-cystic fibrosis bronchiectasis (EMBRACE): a randomised, double-blind, placebo-controlled trial. Lancet. 2012; 380(9842): 660-667 DOI: 10.1016/S0140-6736(12)60953-2
Valery PC, Morris PS, Byrnes CA, et al. Longterm azithromycin forlndigenous children with non-cystic-fibrosis bronchiectasis or chronic suppurative lung disease (Bronchiectasis Intervention Study): a multicentre, double-blind, randomised controlled trial. Lancet Respir Med. 2013; 1(8): 610-620 DOI: 10.1016/S2213-2600(13)70185-1
Stockley R, De Soyza A, Gunawardena K, et al. Phase II study of a neutrophil elastase inhibitor (AZD9668) in patients with bronchiectasis. Respir Med. 2013; 107(4): 524-533 DOI: 10.1016/j.rmed.2012.12.009
Watz H, Pedersen F, Kirsten A, et al. Safety and tolerability of the NE inhibitor BAY85-8501 in patients withnon-CF bronchiectasis. Eur Res J. 2016; 48: PA4088 DOI: 10.1183/13993003.congress-2016.pa4088
Miller BE, Mayer RJ, Goyal N, et al. Epithelial desquamation observed in a phase I study of an oral cathepsin C inhibitor (GSK2793660). Br J Clin Pharmacol. 2017; 83(12): 2813-2820 DOI: 10.1111/bcp.13398
Stenvall K, Mo J, Russel M, et al.Target engagement confirmed in man with a dipeptidyl peptidase 1 inhibitor. Eur Res J. 2017; 50: PA3251. congress-2017.pa3251 DOI: 10.1183/1393003
De Soyza A, Pavord I, Elborn JS, et al. Randomised, placebo-controlled study of the CXCR2 antagonist AZD5069 in bronchiectasis. Eur Respir J. 2015; 46(4): 1021-1032 DOI: 10.1183/13993003.001482015
Wang TT Nestel FP, Bourdeau V, et al. Cutting edge: 1,25-dihydroxyvitaminD3isadirectinducerofantimicrobial peptide gene expression. J Immunol. 2004; 173(5): 2909-2912 DOI: 10.4049/jimmunol.173.5.2909
Chalmers JD, McHugh BJ, Docherty C, et al. Vitamin-D deficiency is associated with chronic bacterial colonisation and disease severity in bronchiectasis. Thorax. 2013; 68(1): 39-47. doi: 10.1136/Thoraxjnl-2012-202125.
Martineau AR, James WY Hooper RL, et al. Vitamin D3 supplementation in patients with chronic obstructive pulmonary disease (ViDiCO): a multicentre, double-blind, randomized controlled trial. Lancet Respir Med. 2015; 3(2): 120-130 DOI: 10.1016/S2213-2600(14)70255-3
Suzuki K, Lee WJ, Hashimoto T, et al. Recombinant granulocyte-macrophage colony-stimulating factor (GM-CSF) or tumour necrosis factor-alpha (TNF-alpha) activate human alveolar macrophages to inhibit growth of Mycobacterium avium complex. Clin Exp Immunol. 1994; 98(1): 169-173 DOI: 10.1111/j.1365-2249.1994.tb06625.x
Onyeji CO, Nightingale CH, Tessier PR, et al. Activities of clarithromycin, azithromycin, and ofloxacin in combination with liposomal or unencapsulated granulocyte-macrophage colony-stimulatingfactor against intramacrophage Mycobacterium avium-Mycobacterium intracellulare. J Infect Dis. 1995; 172(3): 810-816 DOI: 10.1093/infdis/172.3.810
Ballinger MN, Paine R 3rd, Serezani CH, et al. Role of granulocyte macrophage colony-stimulating factor during gram-negative lung infection with Pseudomonas aeruginosa. Am J Respir Cell Mol Biol. 2006; 34(6): 766-774 DOI: 10.1165/rcmb.2005-02460C
Conway Morris A, Kefala K, Wilkinson TS, et al. C5a mediates peripheral blood neutrophil dysfunction in critically ill patients. Am J Respir Crit Care Med. 2009; 180(1): 19-28 DOI: 10.1164/rccm.200812-19280C
Ruchaud-Sparagano MH, Gertig H, Hester KL, et al. Effect of granulocyte-macrophage colony-stimulating factor on neutrophil function in idiopathic bronchiectasis. Respirology. 2013; 18(8): 1230-1235 DOI: 10.1111/resp.12138
Hurst JR, Elborn JS, De Soyza A; BRONCH-UK Consortium. COPD-bronchiectasis overlap syndrome. Eur Respir J. 2015; 45(2): 310-313 DOI: 10.1183/09031936.00170014
Chalmers JD, Short PM, Mandal P, et al. Statins in community acquired pneumonia: evidence from experimental and clinical studies. Respir Med. 2010; 104(8): 1081-1091. doi: 10.1016/j. rmed.2010.04.005.
Mandal P., Chalmers JD, Graham C., et al. Atorvastatin as a stable treatment in bronchiectasis: a randomised controlled trial. Lancet Respir Med. 2014; 2(6): 455-463 DOI: 10.1016/S2213-2600(14)70050-5
Bedi P., Chalmers JD, Graham C., et al. A randomized controlled trial of atorvastatin in patients with bronchiectasis infected with Pseudomonas aeruginosa: a proof of concept study. Chest. 2017; 152(2): 368-378 DOI: 10.1016/j.chest.2017.05.017
O’Donnell AE, Barker AF, Ilowite JS, Fick RB. Treatment of idiopathic bronchiectasis with aerosolized recombinant human DNase I. rhDNase Study Group. Chest. 1998; 113(5): 1329-1334 DOI: 10.1378/chest.113.5.1329
Bilton D., Tino G., Barker AF, et al. Inhaled mannitol for non-cystic fibrosis bronchiectasis: a randomised, controlled trial. Thorax. 2014; 69(12): 1073-1079 DOI: 10.1136/thoraxjnl-2014-205587
Casals T., De-Gracia J., Gallego M., et al. Bronchiectasis in adult patients: an expression of heterozygosity for CFTR gene mutations? Clin Genet. 2004; 65(6): 490-495 DOI: 10.1111/j.0009-9163.2004.00265.x
Bienvenu T., Sermet-Gaudelus I., Burgel PR, et al. Cystic fibrosis transmembrane conductance regulator channel dysfunction in non-cystic fibrosis bronchiectasis. Am J. Respir Crit Care Med. 2010; 181(10): 1078-1084 DOI: 10.1164/rccm.200909-14340C
Зыков К.А. Морфофункциональная оценка эффективности лечения эндогенной бронхиальной астмы ингаляциями ультрамалых доз мелфалана: Автореф. дис. канд. мед. наук. -М.; 2000. -22 с. Moscow; 2000. 22 р. (In Russ).] Источник не найден.
Зыков К.А. Клинико-иммунологические и морфологические изменения при терапии бронхиальной астмы иммунодепрессивными препаратами: Дис. докт. мед. наук. -М.; 2009. -219 с. Доступно по: http://www.dissercat.com/content/kliniko-immunologicheskie-i-morfologicheskie-izmeneniya-pri-terapii-bronkhialnoi-astmy-immun. Ссылка активна на 12.11.2018.
Pukhalsky A., Toptygina A., Khaudukov S. Interleukin-2 receptor beta chain as a possible target for low doses of mafosfamide. Mediators Inflamm. 1995; 4(3): 175-180 DOI: 10.1155/S0962935195000287
Pukhalsky AL, Shmarina GV. Stimulatory and protective effects of alkylating agents applied in ultra-low concentrations. Pharmacology. 2001; 62(3): 129-132 DOI: 10.1159/000056084
Gao YH, Guan WJ, Liu SX, et al. Aetiology of bronchiectasis in adults: a systematic literature review. Respirology. 2016; 21(8): 1376-1383 DOI: 10.1111/resp.12832

Еще

Статья обзорная